(MedPage Today) — SAN FRANCISCO — Incorporating the recently approved bispecific antibody zanidatamab (Ziihera) into first-line treatment for HER2-positive gastroesophageal cancer topped trastuzumab plus chemotherapy, a phase III trial showed…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
